In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Lymphoma - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

  • Studying Immune System Reconstitution Following Unrelated Donor Transplantation and Graft-Versus-Host-Disease Prevention
    (Posted: 01/13/2009) - Patients with high-risk, advanced hematologic malignancies will undergo induction chemotherapy, reduced-intensity immune-depleting chemotherapy, and allogeneic stem cell transplantation from a matched, unrelated donor, followed by graft-versus-host disease prevention.
  • Treating Relapsed or Refractory B-cell Lymphomas
    (Posted: 07/22/2008) - Scientists are studying the drug flavopiridol in this early phase clinical trial to see if it can be effective in treating diffuse large B-cell lymphoma and mantle cell lymphoma that has relapsed or been resistant to treatment.
  • Batracylin for Patients with Advanced Solid Tumors or Lymphoma
    (Posted: 04/01/2008) - In this phase I trial, patients with solid tumors or lymphomas for which standard therapies do not exist or are of minimum benefit and who are slow acetylators, as determined by a blood test, will be treated with increasing doses of the drug batracylin.
  • New Targeted Therapy for Solid Tumors and Lymphomas
    (Posted: 08/10/2004, Updated: 07/18/2007) - In this trial, researchers are trying to determine whether a new chemotherapy agent called 17-DMAG will help prevent cancer cells from growing in patients with solid tumors or lymphomas. The agent inhibits a protein called HSP-90 that is found more often in cancer cells than in normal cells.
  • Targeted Therapy for Lymphoid Cancers
    (Posted: 05/29/2007) - Patients with T-cell or B-cell lymphoid cancers that have recurred or progressed despite prior chemotherapy will receive the drug ABT-263 orally for up to a year in this phase I/II clinical trial.
< Previous  1 2 3 4 5  Next >